Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna is rapidly developing its pipeline of product candidates, with a focus on treating patients in three key therapeutic areas. The company is making significant progress in its clinical development, with plans to initiate a Phase 2b trial for its lead candidate SEP-631 in second half of 2026. In addition, Septerna has multiple other programs in various phases of development and is also advancing its oral small molecule PTH1R agonist program for hypoparathyroidism. The company has a strong partnership with Novo Nordisk in obesity and is utilizing its proprietary Native Complex Platform to develop treatments for various diseases. With a discounted cash flow-based valuation and conservative assumptions, Septerna has a price objective of $35 per share. However, potential risks such as delays in clinical development and partnership risks should be considered. Upcoming catalysts include the company's plans to initiate a Phase 1 trial for its PTH1R agonist candidate, as well as the release of clinical data for SEP-631 in the first half of 2026.

Bears say

Septerna is a clinical-stage biotechnology company that has a promising pipeline of product candidates in three therapeutic areas; however, its current enterprise value of only $430M does not accurately reflect the potential value of its obesity candidates, as shown by the recent M&A battle between Novo and Pfizer. Additionally, Septerna is making progress in advancing its lead compounds in its TSHR-NAM program and continues to explore new therapeutic areas through its partnership with Novo. Despite these positive developments, the stock still faces significant risk and uncertainty in preclinical and clinical trials, making it a risky investment.

Septerna Inc (SEPN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.